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A yeast aspartic acid tRNA with a 5’ extension of 14 nucleotides was obtained by in vitro transcription with T7 DNA dependent RNA polymerase. 
This transcript, called extended tRNAAsr transcript, retains its aspartylation capacity with the same Km and only three times reduced k,, values 
as compared to those measured for canonical tRNAAsr. This result indicates that the 5’ extension of the amino acid acceptor stem of tRNA*“r 
does not interfere with recognition by aspartyl-tRNA synthetase. However, in contrast o the wild-type tRNA@ transcript, the 5’ extended molecule 
presents a reduced capacity to be mischarged by arginyl-tRNA synthetase, suggesting the existence of different structural requirements in aspartyl- 
and arginyl-tRNA synthetases for tRNAASr recognition. 
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1. INTRODUCTION 
The requirements that lead to specific recognition 
between tRNAs and aminoacyl-tRNA synthetases are 
still not known in detail and their knowledge represents 
one of the major prerequisites for a thorough 
understanding of the translation of the genetic message. 
Besides crystallography [l-3], one classical way to ap- 
proach this problem is to induce changes in the tRNA 
molecules and to study their effects on their 
aminoacylation activities (e.g. [4]). The development of 
RNA engineering method and of in vitro transcriptional 
systems now gives the opportunity to create a variety of 
mutations in the wild-type molecules. This 
methodology yields tRNAs without modified 
nucleotides but which fully retain their aminoacylation 
properties as far as the wild-type molecules have been 
investigated (e.d. [5-7]), although they can acquire new 
specificities [7]. 
To better understand the relationship between the 
structure of tRNAASp near its amino acid accepting end 
and its aspartylation capacity, a variant tRNAAsp 
molecule was created (called extended tRNAASp 
transcript) with a 14 nucleotide-long extension at the 5 ’ 
end of the molecule (Fig. 1). This was achieved by site 
directed mutagenesis of a modified pUC 18 plasmid 
containing the wild-type synthetic gene of tRNAASp 
starting with the T7 promoter. The aspartylation 
capacity and the mischarging ability of the in vitro 
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transcripts of this gene were assayed in the presence of 
aspartyl- and arginyl-tRNA synthetases. The results will 
be discussed in relation with tRNA precursors [8], 
tRNA-like structures [9-l 11, and the structural re- 
quirements at the 5 ’ termini of tRNAs for recognition 
by aminoacyl-tRNA synthetases. 
2. MATERIALS AND METHODS 
2.1. tRNA, enzymes and chemicals 
Fully modified yeast RNAAsp was purified by chromatographies on 
BD-cellulose and Sepharose 4B columns after counter-current 
distribution of bulk brewer’s yeast tRNA (Boehringer Mannheim, 
France SA, Meylan) [12,13]. Unmodified tRNAAsp molecules were 
obtained by in vitro transcription of Bst Nl linearized plasmid PTA 
(variant pGlC72, called transcript A) as described previously [7,14]. 
Pure yeast aspartyl-tRNA synthetase was prepared as described in [2] 
and pure arginyl-tRNA synthetase by a procedure derived from 
[ 15,161. The T7 RNA polymerase was purified according to King et al. 
[17]. RNasin was from Promega (Madison WI, USA); 
pyrophosphatase from Sigma (St. Louis, MO, USA), L-[‘Hlaspartic 
acid at 32 Ci/mole and L-[‘Hlarginine at 57 Ci/mole from Amersham 
France (Les Ulis), and restriction enzymes from Boehringer Mann- 
heim France SA (Meylan). For mutagenesis experiments, the Amer- 
sham kit (ref. RPN 1523) was used. 
2.2. Cloning and site directed mutagenesis of the synthetic tRNAAEp 
gene 
Plasmid pTA containing the variant (Cl-C72) gene of tRNAASp was 
constructed as described in [7,14]. To perform site-directed 
mutagenesis on single-stranded DNA, a new plasmid pTFMA was 
created by insertion of phage fl intergenic region into plasmid PTA 
according to Vernet et al. [18]. The tRNAAsP gene (Cl-C72 variant) 
was then excised from this new plasmid and replaced by a synthetic 
gene corresponding to the wild-type sequence (Ul, A72 1191) of 
tRNAASp. After transformation of E. coli strain JM103 by this 
plasmid called pTFMWT, infection of the cells with filamentous 
helper phage M13K07, single-stranded DNA with the complementary 
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tRNAASp sequence was prepared following standard procedures 
(Pharmacia Analects 14-1, 1986). For further experimental details see 
WI. 
The insertion of a 1Cnucleotide long extension between the T7 
RNA polymerase promoter and the tRNAAsp sequence by site-directed 
mutagenesis of single stranded DNA from pTFMWT was done 
following the procedure of Eckstein and coworkers [21] as described 
in the Amersham mutagenesis kit. The following 35nucleotlde long 
oligonucleotide (ACTCACTATAGCGCAACCGTATTGTCCG- 
TGATAG) was used for the mutagenesis, with the 5’ extension in- 
dicated in bold characters. The sequence of the gene was verified us- 
ing the T7 DNA polymerase methodology [22]. 
2.3. In vitro transcription 
Transcription of the extended tRNAASp gene follows essentially the 
conditions used for PTA [7,14]. Conditions were 40 mM Tris-HCl, 
pH 8.1, 22 mM MgCl2, 1 mM spermidine, 5 mM dithioerythritol, 
0.01% Triton X-100, 4 mM NTP (of each), 16 mM GMP, 40 units 
RNasin, 0.55 units pyrophosphatase (Sigma, USA), and 80 mg Bst Nl 
linearized DNA and 3000 units T7 RNA polymerase per ml of incuba- 
tion mixture. Typical transcriptions were carried out in 150 pl. After 
3 h of incubation at 37°C transcripts were phenol extracted, purified 
by electrophoresis on 10% polyacrylamide/l M urea gels, and elec- 
troeluted. Due to the presence of GMP in the transcription media, 
%% of the transcripts start with a 5 ’ monophosphate as verified by 
TLC analysis. 
2.4. Aminoacylation of tRNAs 
Aspartylation of tRNAs was performed in a buffer containing 100 
mM Tris-HCl (pH 7.2), 5 mM ATP, 10 mM MgCl2 and 30 mM KCI. 
Arginylation assays were conducted in a buffer containing 50 mM 
Tris-HCl @H 7.5), 10 mM ATP, 15 mM MgCl2,30 mM KCl, 2.5 mM 
glutathione and 50 PM radioactive amino acid. The plateau levels of 
aspartylation and arginylation were determined with concentrations 
of 200 nM of tRNA and 30 nM of the specific aminoacyl-tRNA syn- 
thetase. Initial velocities for aspartylation were obtained in the 
presence of pure aspartyl-tRNA synthetase at a final concentration of 
2.5 nM and in a concentration range of tRNA from 2 to 20 nM. Initial 
velocities for arginylation were obtained in the presence of pure 
arginyl-tRNA synthetase at a final concentration of 30 or 3 nM and 
in a concentration range of transcripts from 75 to 330 nM or 300 to 
1500 nM for the extended or wild-type transcripts, respectively. 
Aminoacylation results were determined as trichloroacetic acid 
precipitable radioactivity. Data from kinetic experiments were analyz- 
ed on Lineweaver-Burk plots. 
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Fig. 1. Cloverleaf secondary structure of extended tRNAAsP Fig. 2. Aspartylation plateaus of canonical modified yeast tRNAASP, 
transcript. The sequence of the tRNA (nucleotides l-76) is according and of the two tRNAAaP transcripts, variant (pGl-C72) and extended 
to [19]. The nucleotide sequence of the extension is given in bold tRNAAsP. The aminoacylation reactions were conducted on 100 ~1 
characters. samples and each experimental point corresponds to 20 ~1 aliquots. 
3. RESULTS AND DISCUSSION 
3.1. Design and transcription of extended tRNAASp 
gene 
The sequence of the extension introduced at the 5 ’ 
end of tRNAASp was chosen according to three criteria: 
(i) to keep free the 4 nucleotides of the 3 ’ end of the 
tRNA (G73C74C75A76); (ii) to prevent internal secon- 
dary structure in the 1Cnucleotide long extension and 
to prevent refolding of the transcript; (iii) to give an op- 
timized start to transcription [23]. Thus the sequence 
(A-4U-3U-2G-1) has been chosen for the 3’ part of the 
extension and three contiguous G residues 
(G-14G-13G-12) have been introduced at its 5’ end. 
Further, the internal portion of the extension consists 
of a random sequence without possibilities of Watson- 
Crick base pairings. We note that the sequence of the 
extension differs from that of the spacer region, 
lo-nucleotide long, which was found upstream of 
tRNAASP in the Saccharomyces cerevisiae gene contain- 
ing the dimeric tRNAhg3-tRNAASP precursor [23]. 
As expected the transcription level of the extended 
tRNAASP is high and the yield of PAGE purified RNA 
is 50 pg for a typical 150 ~1 incubation. It is comparable 
to that of the (pGl-C72) variant and much better (about 
100 fold) than that of the wild-type (pUl-A72) molecule 
171. 
3.2. Aminoacylation of extended tRNAASp transcript 
In a previous study, we have demonstrated that both 
(pUl-A72) and (pGlC72) tRNAASp variants can be 
aspartylated as efficiently as modified natural tRNAASp 
[7]. Since the (pGl-G72) variant is active and can be 
easily transcribed, it was used rather than the 
(pUl-A72) molecule as a control in this work. 
3.2.1. Aspartylation of extended tRNAASp transcript 
Fig. 2 displays comparative aspartylation assays con- 
ducted on extended tRNAASp transcript (pGlC72) 
tRNAASP transcript, and natural modified tRNAASp. As 
could not be predicted a priori, the extended transcript 
is efficiently aspartylated as compared to the control 
Time (mn) 
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tRNAs. Not only a 83% to 90% aspartylation level is 
observed for the extended molecule, but also its kinetic 
parameters are very similar to those of the controls 
(Table I). Indeed the Michaelis-Menten constant, K, of 
tRNAASp is 60 nM, whereas that of the extended 
molecule is 76 nM. A small difference is found for the 
k,,, value of the extended transcript, which is three 
times lower than that of native tRNAASp. Further the 
specificity constants k&K, are quasi-identical for the 
different kinds of tRNA. These results clearly show that 
the presence of 14 extra-bases at the 5 ’ end of tRNAASp 
does neither prevent the recognition by aspartyl-tRNA 
synthetase, nor the formation of a catalytically active 
complex. 
3.2.2. Arginylation of extended tRNAAsp transcript 
Beside being aspartylatable, tRNAASp transcripts, 
either wild-type or the pGlC72 variant, exhibit par- 
ticular functional characteristics compared to the 
natural tRNAASp: they are efficiently mischarged by the 
non-cognate side arginyl-tRNA synthetase 171. In the 
present work, we show that the extended tRNAASp 
transcript is also recognized and aminoacylated by 
arginyl-tRNA synthetase. As presented in Fig. 3, the 
arginylation level of the extended transcript is signifi- 
cant (36%) and much higher than that of modified 
tRNAASp @‘J/o). However, this level is not as high as that 
of the pGlC72 transcript which reaches 80%. Thus, 
recognition by arginyl-tRNA synthetase is influenced 
by the presence of the extension in the transcript. As 
seen in Table I, the influence of the extra-bases i  essen- 
tially expressed at the level of the reaction rate as 
reflected by a ten fold lower kcat for the mutant than for 
the wild-type transcript. The slightly better K, for the 
arginylation of the extended molecule could reflect an 
enhanced affinity of the variant molecule for arginyl- 
tRNA synthetase due to nonspecific interactions of the 
extension with the synthetase. A similar effect was 
observed for the TYMV tRNA-like molecules interac- 
ting with valyl-tRNA synthetases [24]. As a conse- 
quence, the specificity constant kcat/K,,, for mischarging 
is only slightly decreased in the case of the extended 
molecule, the kCat effect being compensated by the K,,, 
effect. 
0 10 20 30 
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Fig. 3. Arginylation plateaus of canonical modified yeast tRNA@, 
and of the two tRNAASp transcripts, variant (pGl-C72) and extended 
tRNAASp. Aminoacylation reactions were conducted as described in 
Fig. 2. 
3.3. Role of the 5 ’ end of tRNA for aminoacylation 
Earlier footprinting experiments of tRNAASp in con- 
tact with aspartyl-tRNA synthetase [13] as well as the 
low resolution crystal structure of the aspartic acid 
complex [l], have shown that the tRNA interacts with 
the protein through the face comprising the variable 
region. Since aspartylation remains efficient with ex- 
tended tRNAASp, it implies that the 5 ’ terminus does 
not interfere with complex formation and/or 
aminoacylation activity. A likely structural explanation 
would be that the nucleotide sequence of the tRNA 
presents a kink between residues 1 and - 1, allowing the 
extension to leave the enzyme surface. Consequently 
the region in tRNA around residue 1 seems not to be im- 
portant for aspartylation, a conclusion also supported 
by other independent experimental evidences. Indeed 
the wild-type sequence of the tRNA could be mutated 
from Ul-(A72) to Gl-(C72) without a loss of the 
aminoacylation activity, contrarily to what could be ex- 
pected from sequence comparison of yeast tRNAs that 
points to a strong correlation between the nature of this 
nucleotide and aspartic acid identity [25]. Further, the 
5 ’ end of the tRNA, normally starting with a 
monophosphate group could be replaced by a 
triphosphate without affecting the aspartylation activi- 
ty [71. 
It can be questioned whether these properties and 
structural implications apply to other tRNA 
aminoacylation systems. As far as the phosphorylation 
Table I 
Kinetic parameters of aminoacylation of modified tRNAASp, (pGl-C72) and extended tRNA Asp transcripts by yeast aspartyl- and arginyl-tRNA 
synthetases 
Plateau k cat &I kc,,/Km 
(s - ‘) (nM) (relative) 
Aspartyi-tRNA synthetase 
native tRNAASp 100 0.60 60 100 
(pGl-C72) variant 96 0.69 60 115 
extended transcript 85 0.22 76 29 
Arginyl-tRNA synthetase 
(pGl-C72) variant 80 0.11 1300 100 
extended transcript 36 0.012 430 33 
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of the 5’ termini is concerned, it is known for instance 
that triphosphorylated tRNAPhe transcript [5] or non- 
phosphorylated E. coli tRNAfMef [26] and yeast 
tRNAPhe [27] can also be charged. Larger structural 
changes are found at this location in tRNA-like ends of 
viral genomes. In that case the acceptor arm involves a 
pseudo-knotted folding in which nucleotides equivalent 
to residues - 1 (or more upstream) of a 5 ’ extension of 
a canonical tRNA are found (see for instance the 4 
nucleotides from loop Ll in the tRNA-like structure of 
TYMV [28]). Despite this structural peculiarity, viral 
tRNA-like molecules are efficiently aminoacylated. In 
contrast however, E. coli tRNAHi” which is known to 
have an extra G-l residue at the 5 ’ end of its acceptor 
stem has its aminoacylation activity affected by in- 
troduction of a triphosphate at the 5 ’ terminus [29], but 
this behaviour may be explained by the fact that G-l 
base-pairs with the discriminator residue C73 and thus 
brings the triphosphate group in closer vicinity to the 
catalytic site of the synthetase. 
It is interesting to note that the arginylation ability of 
extended tRNAASp is reduced as compared to that of the 
normal-length tRNA*“* transcript, while its aspartyla- 
tion ability is similar. This means that the recognition 
process of this extended tRNA by arginyl- and aspartyl- 
tRNA synthetases i not exactly the same. Accordingly, 
the protein conformation around the binding sites of 
the tRNA 5 ’ termini is not the same for the two syn- 
thetases which also differ in molecular mass and 
oligomeric structure: al, A4, 74 000 [15], and ~2, M, 
130 000 [30], for arginyl- and aspartyl-tRNA syn- 
thetase, respectively. So, this observation is a further 
evidence that the structure of the synthetase governs the 
interaction of the tRNA [31]. 
3.4. Outlooks 
To date and as far as we know, aminoacylation ex- 
periments on tRNA precursors have not been described. 
While recognition (or charging after addition of the 3 ’ 
terminal CCA) by aminoacyl-tRNA synthetases of 
precursor tRNAs containing introns appears unlikely, it 
may be a likely possibility for other precursors deprived 
of such structural adducts, in particular for the dimeric 
tRNAA”3-tRNAASp precursor from yeast [32]. Could 
such a putative interaction of an aminoacyl-tRNA syn- 
thetase with precursor tRNA have a physiological 
significance? Although it is premature to answer this 
question it might be suggested that synthetases present 
in nuclei [33] could be involved in the regulation of the 
processing of tRNA precursors. From another point of 
view, the study of extended tRNA transcript could 
represent a new way for studying the type of interaction 
of tRNAs with synthetases of different oligomeric 
structures. Finally, from a practical point of view the 
tRNAASp extended transcript could serve to produce 
large quantities of wild-type tRNAASp transcripts star- 
ting with Ul (and thus not easily transcribed in vitro by 
T7 polymerase) after processing with Ml RNA from 
Escherichia coli RNase P [34]. 
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